WallStSmart

CryoCell International Inc (CCEL)vsDaVita HealthCare Partners Inc (DVA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 45416% more annual revenue ($14.17B vs $31.13M). DVA leads profitability with a 6.5% profit margin vs -6.3%. DVA appears more attractively valued with a PEG of 0.47. DVA earns a higher WallStSmart Score of 70/100 (B-).

CCEL

Hold

47

out of 100

Grade: D+

Growth: 6.0Profit: 5.0Value: 7.0Quality: 5.5
Piotroski: 6/9Altman Z: -0.53

DVA

Strong Buy

70

out of 100

Grade: B-

Growth: 6.7Profit: 7.0Value: 7.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCELUndervalued (+33.5%)

Margin of Safety

+33.5%

Fair Value

$5.02

Current Price

$4.15

$0.87 discount

UndervaluedFair: $5.02Overvalued
DVAOvervalued (-9.5%)

Margin of Safety

-9.5%

Fair Value

$131.77

Current Price

$161.03

$29.26 premium

UndervaluedFair: $131.77Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEL3 strengths · Avg: 10.0/10
Return on EquityProfitability
129.2%10/10

Every $100 of equity generates 129 in profit

EPS GrowthGrowth
75.1%10/10

Earnings expanding 75.1% YoY

Debt/EquityHealth
-0.0410/10

Conservative balance sheet, low leverage

DVA5 strengths · Avg: 9.6/10
PEG RatioValuation
0.4710/10

Growing faster than its price suggests

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

EPS GrowthGrowth
66.7%10/10

Earnings expanding 66.7% YoY

Debt/EquityHealth
-22.6610/10

Conservative balance sheet, low leverage

P/E RatioValuation
14.1x8/10

Attractively priced relative to earnings

Areas to Watch

CCEL4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Market CapQuality
$39.10M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.6%3/10

Operating margin of 0.6%

Altman Z-ScoreHealth
-0.532/10

Distress zone — elevated risk

DVA4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

Profit MarginProfitability
6.5%3/10

6.5% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEL

The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : DVA

The strongest argument for DVA centers on PEG Ratio, Return on Equity, EPS Growth. PEG of 0.47 suggests the stock is reasonably priced for its growth.

Bear Case : CCEL

The primary concerns for CCEL are Revenue Growth, Market Cap, Operating Margin.

Bear Case : DVA

The primary concerns for DVA are Revenue Growth, Profit Margin, Piotroski F-Score.

Key Dynamics to Monitor

CCEL profiles as a turnaround stock while DVA is a value play — different risk/reward profiles.

DVA carries more volatility with a beta of 0.86 — expect wider price swings.

DVA is growing revenue faster at 4.6% — sustainability is the question.

DVA generates stronger free cash flow (359M), providing more financial flexibility.

Bottom Line

DVA scores higher overall (70/100 vs 47/100). CCEL offers better value entry with a 33.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CryoCell International Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Want to dig deeper into these stocks?